GRANTS FUNDED in 2007
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
Recent Science Funding Provided
by the Hereditary Disease Foundation
Click here to begin your search
for research updates by HDF-funded scientists and others.
PubMed, a service of the National Library of Medicine, provides access to
over 12 million MEDLINE citations back to the mid-1960's and additional life
science journals.
PubMed includes links to many sites providing full text articles and other
related resources.
Hereditary Disease Foundation grants, postdoctoral fellowships and research contracts are helping identify routes to the development of cures and treatments for Huntington's disease and other similar hereditary disorders. With your support, the HDF's Scientific Advisory Board, comprised of world-renowned experts in genetics, neurology, neuroscience, and therapy development, has funded groundbreaking research. The following projects were recently funded:
RESEARCH GRANTS
Michael Johnson
University of Kansas
Behavioral and neurochemical analysis of transgenic Huntington's disease model rats.
Kimberly Kegel
MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital
Generating neurons from Huntington's disease embryonic stem cells for drug discovery.
2007 Lieberman Award recipient:
Albert La Spada
University of Washington, Seattle WA
Elucidating the mechanism of energy disruption in Huntington's disease.
Karine Merienne
IGBMC, Strasbourg, France
Role of the DNA damage response in Huntington's disease.
Anton Reiner
University of Tennessee
Memphis: Role of striatal parvalbuminergic neurons in dystonia in Huntington's disease.
Paul Rosenberg
Harvard Medical School
The role of glutamate transport in the pathogenesis of Huntington's disease.
Doda Rudnicki
Johns Hopkins University
Clues to HD pathogenesis from HDL2: protein aggregates and the muscleblindlike pathway.
Ghazaleh Sadri-Vakili
MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital
Abnormal huntingtin-MeCP2 interactions lead to transcriptional dysregulation in Huntington's disease.
Gabriele Schilling
Leibniz Institute for Age Research, Fritz Lipmann Institute, Jena, Germany
Identification and inhibition of a novel protease processing huntingtin.
Naoko Tanese
New York University
Role of Huntington's disease protein in post-transcriptional pathways.
POSTDOCTORAL FELLOWSHIPS
Yun-Sik Choi
Ohio State University
Mentors: Karl Obrietan, Kari Hoyt
Neuroprotection by CREB/CRE transcriptional pathway in Huntington's disease.
Kim Holloway
Cornell University
Mentor: Paula Cohen
Mechanisms of mismatch repair protein function in the pathogenesis of Huntington's disease.
Erica Johnson-Rowe
University of Tennessee
Mentor: Ron Wetzel
Characterization of phenotypically distinct aggregates within a Huntingtin inducible PC12 cellular model.
Katherine Steinkraus
University of Washington
Mentor: Matthew Kaeberlein
Suppression of polyglutamine proteotoxicity by dietary restriction in Caenorhabditis elegans.
Andrey Tsvetkov
Gladstone Institute, University of California, San Francisco
Mentor: Steven Finkbeiner
Metabolism of huntingtin in health and disease.
2007 Milton Wexler Postdoctoral Fellowship Recipient:
Jerremy Van Raamsdonk
McGill University, Montreal, Canada
Mentor: Siegfried Hekimi
The role of aging genes in Huntington disease.
Vietminh Paz Villgran
University of Bordeaux, France
Mentor: Yoon Cho
Habit memory coding by striatal cells in HD transgenic mice.
Esther Wong
Albert Einstein University
Mentor: Ana Maria Cuervo
Contribution of ubiquitin linkages to the degradation of Huntingtin by autophagy and proteosome.
RESEARCH CONTRACTS
Marie-Francoise Chesselet
University of California at Los Angeles
Immunohistochemical and electron microscopic analysis of huntingtin aggregates.
Beverly Davidson and Yi Xing
University of Iowa
Exon and microRNA profiling of human HD brains
Beverly Davidson
University of Iowa
Testing viral-encoded anti-huntingtin intrabodies as a potential HD therapy.
Beverly Davidson
University of Iowa
Preclinical development of a gene therapy for Huntington's disease via RNA interference.
Stephen Dunnett and Lesley Jones
Cardiff University, UK
A comparison of behavioral and gene expression changes in rodent models of HD.
Christian Neri
INSERM
Genome wide siRNA in C. elegans to identify targets for HD therapies.
Paul Patterson
California Institute of Technology
Intrabodies as therapeutics for HD.
Alfred Stracher and Leo Kesner
State University of New York Downstate Medical Center
and
Lisa Ellerby
Buck Institute for Age Research
Testing calpain inhibitors in HD mice.
Leslie Thompson and J. Lawrence Marsh
University of California, Irvine
The role of secondary modification of huntingtin protein in the pathogenesis of HD.
X. William Yang
University of California at Los Angeles
Developing HD BAC mice as a new platform for testing putative HD therapies.
|
